Trinity Biotech(US:TRIB)2022-12-07 14:59Company Overview - Trinity Biotech is a global IVD company providing centralized diagnostic products, lateral flow products, and lab-based testing services[5] - The company has a diversified global platform in Diabetes & Autoimmune markets, as well as Point of Care & Home Testing spaces[6] - Trinity Biotech has core competencies in product development, lab services, regulatory processes, manufacturing & supply chain[6] Financial Performance & Projections - FY21 revenue was $93 million, with $72 million excluding COVID-related revenues[6] - The company projects double-digit growth between 2023-2025 and aims to double recurring revenue by 2025[6] - In H1/2022, Premier 9210 (HbA1c Lab) accounted for approximately 30% of revenues[46] - The company is targeting >20% revenue growth in 2024-2025 with a 45% gross margin[79] - The company is targeting an adjusted operating margin of 15%-20%+ by 2025[79] Market & Growth Strategies - The global Point of Care market is projected to reach $50 billion by 2025[37] - The company is targeting 25% of the 180 million tests/year market in Africa with its WHO-approved HIV screening test[43] - The company plans to reposition its PoC platform to high-margin growth strategies[63]